Australia markets open in 7 hours 34 minutes

Tibet Weixinkang Medicine Co., Ltd. (603676.SS)

Shanghai - Shanghai Delayed price. Currency in CNY
Add to watchlist
9.05-0.02 (-0.22%)
At close: 03:00PM CST

Tibet Weixinkang Medicine Co., Ltd.

Building 4
3rd Floor, Industrial Center Lhasa Eco & Tech Dev Zn No. 5, Park South Road, Zone B
Lhasa 850000
China
86 89 1660 1760
https://www.wxkpharma.com

Sector(s)Healthcare
IndustryDrug Manufacturers - Specialty & Generic
Full-time employees701

Key executives

NameTitlePayExercisedYear born
Mr. Yong ZhangChairman of the Board & GMN/AN/A1972
Ms. Yanxia ZhengDeputy Financial Director & Financial DirectorN/AN/A1979
Mr. Feng LiuDeputy GM & DirectorN/AN/A1973
Mr. Shigong ChenDeputy GM & DirectorN/AN/A1973
Mr. Haibo YuBoard SecretaryN/AN/A1979
Mr. Xiaobing ZhouDeputy General ManagerN/AN/A1976
Mr. Zizhong WengDeputy General ManagerN/AN/A1964
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.

Description

Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of chemical drugs and their bulk drugs in China. The company offers parenteral nutrition vitamins, electrolyte supplements, intravenous iron supplements, antibiotics, and medicine for digestive system and liver diseases, and other special fields. It also offers injection multivitamins, potassium magnesium aspartate for injection, iron sucrose injection, potassium aspartate injection, etc. The company was formerly known as Weixinkang Medicine Youxian Gongsi and changed its name to Tibet Weixinkang Medicine Co., Ltd. in 2015. Tibet Weixinkang Medicine Co., Ltd. was founded in 2006 and is based in Lhasa, China.

Corporate governance

Tibet Weixinkang Medicine Co., Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.